Clinically significant cardiotoxicity was found to be low among patients with CRC receiving trifluridine/tipiracil, but occurred even in those without traditional risk factors.

Researchers sought to determine whether adding subcutaneous rituximab to CHOP would improve outcomes for patients with DLBCL in low-resource settings.

The addition of metformin “was generally well tolerated but did not result in the targeted benefit of a 20% reduction in risk of death in an unselected population,” the researchers wrote.

Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.

HealthDay News — Most individuals living in underserved communities believe that dermatologic side effects (DSEs) from anticancer therapies (ACTs) occur at high rates, according to a study published ...

Adjuvant chemoradiation combined with camrelizumab was well tolerated and yielded significantly improved long-term survival,” the researchers wrote.

A quality improvement project incorporated 4 interventions to improve the rate of CLABSIs in pediatric hematology/oncology/bone marrow transplantation patients.

CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues.

Finding seen for patients with chronic lymphocytic leukemia receiving immunoglobulin replacement therapy regularly.

Cancer patients receiving immune checkpoint inhibitor (ICI) therapy may experience more severe toxicity and have a greater risk of death if they have recently used proton pump inhibitors (PPIs), ...

Postmastectomy radiotherapy appeared to increase the risks for minor complications and reoperations after immediate breast reconstruction.

Vascular toxicity associated with cancer therapies is a leading cause of cardiovascular adverse events in patients with ...